OBJECTIVE: To summarize the evidence for the need to improve pharmacologic management of hypertension in people with type 2 diabetes and to provide expert advice on how blood pressure (BP) treatment can be improved in primary care. SOURCES OF INFORMATION: Studies were obtained by performing a systematic review of the literature on hypertension and diabetes, from which management recommendations were developed, reviewed, and voted on by a group of experts selected by the Canadian Hypertension Education Program and the Canadian Diabetes Association; authors' expert opinions on optimal pharmacologic management were also considered during this process. MAIN MESSAGE: The pathogenesis of hypertension in patients with diabetes is complex, involving a range of biological and environmental factors and genetic predisposition; as a result, hypertension in people with diabetes incurs higher associated risks and adverse events. Mortality and morbidity are heightened in diabetes patients who do not achieve BP control (ie, a target value of less than 130/80 mm Hg). Large randomized controlled trials and meta-analyses of randomized controlled trials have shown that reducing BP pharmacologically is single-handedly the most effective way to reduce rates of death and disability in patients with diabetes, particularly associated cardiovascular risks. Often, combinations of 2 or more drugs (diuretics, angiotensin-converting enzyme inhibitors, β-blockers, angiotensin receptor blockers, calcium channel blockers, spironolactone, etc) are required for pharmacotherapy to be effective, particularly for patients in whom BP is difficult to control. However, the health care costs associated with extensively lowering BP are substantially less than the costs associated with treating the complications that can be prevented by lowering BP. CONCLUSION: Detecting and managing hypertension in people with diabetes is one of the most effective measures to prevent adverse events, and pharmacotherapy is one of the most effective ways to maintain target BP levels in primary care.
OBJECTIVE: To summarize the evidence for the need to improve pharmacologic management of hypertension in people with type 2 diabetes and to provide expert advice on how blood pressure (BP) treatment can be improved in primary care. SOURCES OF INFORMATION: Studies were obtained by performing a systematic review of the literature on hypertension and diabetes, from which management recommendations were developed, reviewed, and voted on by a group of experts selected by the Canadian Hypertension Education Program and the Canadian Diabetes Association; authors' expert opinions on optimal pharmacologic management were also considered during this process. MAIN MESSAGE: The pathogenesis of hypertension in patients with diabetes is complex, involving a range of biological and environmental factors and genetic predisposition; as a result, hypertension in people with diabetes incurs higher associated risks and adverse events. Mortality and morbidity are heightened in diabetespatients who do not achieve BP control (ie, a target value of less than 130/80 mm Hg). Large randomized controlled trials and meta-analyses of randomized controlled trials have shown that reducing BP pharmacologically is single-handedly the most effective way to reduce rates of death and disability in patients with diabetes, particularly associated cardiovascular risks. Often, combinations of 2 or more drugs (diuretics, angiotensin-converting enzyme inhibitors, β-blockers, angiotensin receptor blockers, calcium channel blockers, spironolactone, etc) are required for pharmacotherapy to be effective, particularly for patients in whom BP is difficult to control. However, the health care costs associated with extensively lowering BP are substantially less than the costs associated with treating the complications that can be prevented by lowering BP. CONCLUSION: Detecting and managing hypertension in people with diabetes is one of the most effective measures to prevent adverse events, and pharmacotherapy is one of the most effective ways to maintain target BP levels in primary care.
Authors: E J Lewis; L G Hunsicker; W R Clarke; T Berl; M A Pohl; J B Lewis; E Ritz; R C Atkins; R Rohde; I Raz Journal: N Engl J Med Date: 2001-09-20 Impact factor: 91.245
Authors: Daniel G Hackam; Nadia A Khan; Brenda R Hemmelgarn; Simon W Rabkin; Rhian M Touyz; Norman R C Campbell; Raj Padwal; Tavis S Campbell; M Patrice Lindsay; Michael D Hill; Robert R Quinn; Jeff L Mahon; Robert J Herman; Ernesto L Schiffrin; Marcel Ruzicka; Pierre Larochelle; Ross D Feldman; Marcel Lebel; Luc Poirier; J Malcolm O Arnold; Gordon W Moe; Jonathan G Howlett; Luc Trudeau; Simon L Bacon; Robert J Petrella; Alain Milot; James A Stone; Denis Drouin; Jean-Martin Boulanger; Mukul Sharma; Pavel Hamet; George Fodor; George K Dresser; S George Carruthers; George Pylypchuk; Ellen D Burgess; Kevin D Burns; Michel Vallée; G V Ramesh Prasad; Richard E Gilbert; Lawrence A Leiter; Charlotte Jones; Richard I Ogilvie; Vincent Woo; Philip A McFarlane; Robert A Hegele; Sheldon W Tobe Journal: Can J Cardiol Date: 2010-05 Impact factor: 5.223
Authors: G L Bakris; M Williams; L Dworkin; W J Elliott; M Epstein; R Toto; K Tuttle; J Douglas; W Hsueh; J Sowers Journal: Am J Kidney Dis Date: 2000-09 Impact factor: 8.860
Authors: William C Cushman; Gregory W Evans; Robert P Byington; David C Goff; Richard H Grimm; Jeffrey A Cutler; Denise G Simons-Morton; Jan N Basile; Marshall A Corson; Jeffrey L Probstfield; Lois Katz; Kevin A Peterson; William T Friedewald; John B Buse; J Thomas Bigger; Hertzel C Gerstein; Faramarz Ismail-Beigi Journal: N Engl J Med Date: 2010-03-14 Impact factor: 91.245
Authors: Jacky T P Siu; Aaron M Tejani; Vijaya Musini; Ken Bassett; Barbara Mintzes; Jim Wright Journal: Can Fam Physician Date: 2012-01 Impact factor: 3.275
Authors: Norm R C Campbell; Richard E Gilbert; Lawrence A Leiter; Pierre Larochelle; Sheldon Tobe; Arun Chockalingam; Richard Ward; Dorothy Morris; Ross T Tsuyuki; Stewart Harris Journal: Can Fam Physician Date: 2012-06 Impact factor: 3.275
Authors: Aaron M Tejani; Jacky T P Siu; Jim M Wright; Ken Bassett; Vijaya Musini; Barbara Mintzes; Tom Perry Journal: Can Fam Physician Date: 2012-08 Impact factor: 3.275
Authors: Chao Ma; Jeroen H F de Baaij; Paul J Millar; Victor A Gault; Bastiaan E de Galan; René J M Bindels; Joost G J Hoenderop Journal: Nephron Date: 2019-02-22 Impact factor: 2.847
Authors: Daniel T Dibaba; Pengcheng Xun; Yiqing Song; Andrea Rosanoff; Michael Shechter; Ka He Journal: Am J Clin Nutr Date: 2017-07-19 Impact factor: 7.045